Momenta Pharmaceuticals, Inc. (MNTA) Given Average Rating of “Hold” by Analysts
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has received an average rating of “Hold” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating and nine have issued a hold rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.44.
A number of brokerages recently issued reports on MNTA. Stifel Nicolaus reissued a “hold” rating and issued a $15.00 price objective (down from $22.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, October 4th. Zacks Investment Research lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Barclays reissued an “equal weight” rating and issued a $16.00 price objective (down from $17.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and issued a $14.00 price objective (down from $18.00) on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Finally, Cowen set a $15.00 price objective on Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 1st.
In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.35, for a total value of $54,948.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total value of $678,743.01. Following the completion of the sale, the president now owns 286,121 shares of the company’s stock, valued at $5,444,882.63. The disclosure for this sale can be found here. Insiders sold 44,006 shares of company stock valued at $789,369 over the last 90 days. 4.40% of the stock is currently owned by insiders.
Momenta Pharmaceuticals (NASDAQ:MNTA) opened at $13.35 on Thursday. Momenta Pharmaceuticals has a fifty-two week low of $11.85 and a fifty-two week high of $19.90.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. The company had revenue of $24.09 million during the quarter, compared to analyst estimates of $29.58 million. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The business’s revenue was down 17.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.26) earnings per share. analysts expect that Momenta Pharmaceuticals will post -1.16 EPS for the current year.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.